Stock Market Reviews

PCRX (Pacira BioSciences, Inc.) News

Get the latest news, insights, and market updates on PCRX (Pacira BioSciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
  Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
  Jan 12, 2026 - $PCRX
• How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue
  Pacira BioSciences recently reported preliminary unaudited 2025 revenue of US$726.4 million, up from US$701.0 million in 2024, and completed a US$150.05 million buyback repurchasing 5,932,106 shares since May 2025. On top of record EXPAREL volume growth, the company now faces pressure from activist DOMA Perpetual Capital Management, which is pushing for board changes and a potential sale process. With Pacira pairing strong preliminary EXPAREL-driven revenue with an aggressive share...
  Jan 10, 2026 - $PCRX
• Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
  -- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended
  Jan 8, 2026 - $PCRX
• Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
  BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of t
  Jan 7, 2026 - $PCRX
• DOMA intends to nominate three director candidates at Pacira annual meeting
  DOMA Perpetual Capital Management, which beneficially owns approximately 6.83% of the outstanding shares of Common Stock of Pacira (PCRX) BioSciences, announced that it intends to nominate three independent director candidates at the Company’s 2026 annual meeting of stockholders. DOMA further asserts the Company’s Board of Directors should pursue an immediate sale of the Company. DOMA considers the current level of Executive Compensation and General Spending to be exorbitant and unmerited and qu
  Dec 31, 2025 - $PCRX
• DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
  DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 6.83% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), today announced that it intends to nominate three highly-qualified, independent director candidates at the Company's 2026 annual meeting of stockholders. DOMA further asserts the Company's Board of Directors should pursue an immediate sale of the Company. DOMA con
  Dec 30, 2025 - $PCRX
• Pacira BioSciences (PCRX): Reassessing Valuation After a 45% Year‑to‑Date Share Price Rally
  Pacira BioSciences (PCRX) has quietly put together a strong run this year, with shares up around 45% year to date as investors warm to its non opioid pain management and regenerative health focus. See our latest analysis for Pacira BioSciences. That move has come as investors reassess Pacira’s growth profile, with steady adoption of its non opioid portfolio and improving profitability helping offset a softer 90 day share price return. Momentum now looks to be rebuilding after years of weak...
  Dec 18, 2025 - $PCRX
• Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
  --Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints u
  Dec 18, 2025 - $PCRX
• 5 Biotech Stocks to Watch for Potential Upside
  New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
  Dec 17, 2025 - $PCRX
• Pacira BioSciences Stock Earns Technical Rating Upgrade
  Pacira BioSciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
  Dec 16, 2025 - $PCRX